groups compared with the control and insulin-treated groups. After 24 h of diabetes, kidney insulin-like growth factor-1 content was significantly increased from baseline levels in groups DR DL and DH but by 48 h these levels had returned to normal. Renal tissue angiotensin converting enzyme activity was similar in groups C and DI but significantly reduced in all trandolapril-treated animals. Despite inhibiting renal angiotensin converting enzyme activity renal enlargement with increased tissue insulin-like growth factor-1 still occurred. This suggests that neither angiotensin II nor glomerular hyperfiltration, with raised intraglomerular pressure, play a role in the initial renal enlargement seen in experimental diabetes. Renal accumulation of insulin-like growth factor-1 appears to be an important factor in early renal hypertrophy and its effects are not modulated by angiotensin converting enzyme or angiotensin II. [Diabetologia (1996) 39: 166-171] glomerular pressure, has been implicated in the initiation and progression of diabetic nephropathy [1] [2] [3] , the renal hypertrophy being a compensatory change attempting to normalise the glomerular filtration rate (GFR) and intraglomerular pressure. This suggests that increased single nephron GFR, leading to glomerular hyperfiltration, per se stimulates renal hypertrophy [4, 5] . The initial renal growth observed in experimental diabetes or after surgical ablation of renal tissue is preceded by an increase in renal tissue insulin-like growth factor 1 (IGF-1) concentration implying a (patho)physiologi-cal role for growth factors [6, 7] . Acute infusion of IGF-1 causes an acute increase in renal plasma flow (RPF) and GFR which could be a further stimulus to renal hypertrophy [8- 
101.
Our hypothesis is that hyperglycaemia causes increases in IGF-1 leading to increases in RPF, GFR and intraglomerular pressure. If raised intraglomerular pressure is the main stimulus for renal enlargement then treatment with angiotensin converting enzyme (ACE) inhiNtors, which will normalise intraglomerular pressure, should prevent renal enlargement independent of the accumulation of IGF-1. To examine this hypothesis we investigated the effects of trandolapril, a long-acting ACE inhibitor which strongly inhibits tissue ACE, on renal enlargement during the first week of experimental diabetes. Two doses of trandolapril were used; a low dose which would reduce intraglomerular pressure with little reduction in systemic arterial pressure; and a higher dose which reduced systemic arterial pressure.
Materials and methods

Animals. Male Wistar rats bred by the Comparative Biology
Centre (University of Newcastle upon Tyne), with a body weight of 182 +_ 1.1 g (mean + SEM) were studied. Diabetes was induced by i. v. injection of streptozotocin (pH 4.0) (Sigma, Poole, Dorset, UK) in a dose of 55 mg. kg -1 body weight on day 0. All animals were weighed, had tail vein blood glucose measured (One Touch II; Lifescan, Johnson and Johnson, High Wycombe, Bucks., UK), and urinalysis for glucose and ketones (Keto Diastix; Bayer Diagnostics, Stoke Poges, UK) was performed on a daily basis. Rats were housed six to a cage in a room with a 12:12 h (07.00-19.00 hours) artificial light cycle, temperature 21 • 2 ~ and humidity 50 + 4 %. The animals had free access to water throughout the experiment. Three days before commencing the study the animals were matched for body weight and randomized into seven groups: C, non-diabetic, placebo treated CL, non-diabetic, low-dose trandolapril CH, non-diabetic, high-dose trandolapril DE diabetic, placebo treated DL, diabetic, low-dose trandolapril DH, diabetic, high-dose trandolapril DI, diabetic, placebo, insulin
Previous studies showed that high-dose trandolapril (Roussel UCLAF, Paris, France) 0.5 mg. kg -1 9 day < suppressed renal tissue ACE activity by 96 % and reduced the rise in systolic blood pressure following the induction of diabetes by 20 % (29mmHg), while the low-dose trandolapril, 0.01 rag. kg q 9 day 1, suppressed renal tissue ACE activity by 86 % and reduced the rise in systolic blood pressure by 14% (21 mmHg). Trandolapril or placebo (solvent, 1 mmol 1-1. NaOH solution) was injected s.c. daily. Animals in group DI were given 8 units of IU40 long-acting heat-treated ultralente insulin (Novo Nordisk, Copenhagen, Denmark) on day 0. Thereafter, the dose was adjusted daily, according to blood glucose concentration, to maintain normoglycaemia. Insulin, trandolapril and placebo treatments commenced immediately after injection of streptozotocin. On day 0 ten untreated animals were killed. Under halothane anaesthesia blood was removed 167 by cardiac puncture, cervical dislocation was performed and both kidneys were rapidly removed, then divided into two sections (upper and lower); all sections were weighed, then wrapped in tin foil and snap-dried in liquid nitrogen. Tissue was stored at -70 ~ until tissue protein, IGF-1 and ACE activity were determined. On day 1 animals from groups D, DL, and DH were killed, whilst on days 2, 4 and 7 animals from all groups were killed. Serum and plasma were stored at -40 ~ before analysis of IGF-1 and renin activity.
Protein determination. The left lower kidney section was homogenised in 2 mol -1 1 NaOH and the protein content determined using the method of Lowry et al. [11] on an automated Cobas Bio machine (Roche, Welwyn Garden City, Herts., UK).
IGF-1 and A CE determination. The right lower kidney sections
were homogenized in i mol. 1-1 acetic acid in an ice bath (5 ml acetic acid/1000 mg tissue). The tissue was extracted twice and, after lyophilization, samples were re-dissolved in 40 mmol. 1-1 phosphate buffer (pH 8.0). Tissue extracts were kept at -20 ~ until IGF-1 assay was performed in dilute extracts (1:60). IGF-1 was determined by radioimmunoassay using a polyclonal IGF-1 antibody (Nichols Institute Diagnostics, San Juan Capistrano, Calif., USA). The intra-assay coefficient of variation was 5.4 % and inter-assay was 9.3 %.
Renal tissue ACE activity was measured using a radiometric assay [12] and plasma renin measured using a radioimmunoassay.
Statistical analysis
The data are expressed as the mean + SEM unless otherwise stated. Analysis between groups was carried out by one-way analysis of variance and significant differences tested using unpaired t-tests or a Mann-Whitney test as appropriate, corrected for multiple comparisons using the Bonferroni method. (Figs. 1 and2) . All animals given streptozotocin developed diabetes; mean blood glucose concentration was 14.1 _+ 1.1 mmol. 1-1 after 24 h. Blood glucose level in the groups DR DL and DH was more than 15 mmol -1-1 after 24 h and remained significantly raised to a similar extent in these three groups throughout the study (p < 0.001 compared to C), whilst in the insulin-treated group (DI) blood glucose level was comparable to that of the control group from day 2 until day 7. Groups DR DL and DH failed to gain weight for the first 48 h. Thereafter, weight gain paralleled that of the control group although at all time points body weight remained lower in the diabetic animals. The insulin-treated diabetic animals did not lose weight and their weight gain was similar to the non-diabetic, placebo, low-dose and high-dose trandolapril-treated animals.
Results
Blood glucose and body weight
Kidney growth and protein content (Fig. 3) . Kidney weight in groups DR DL and DH was greater than group C from day 2 until day 7. On day 7 kidney weight in all three diabetic groups not treated with insulin was similar to but greater than of all non-diabetic groups (790 + 28 mg C; 1100 + 30 DP; 1010 _+ 30 DL and 1070 _+ 50 DH). Kidney weight in DI was similar to C (C 790 + 28 vs DI 800 + 43 mg). Protein concentration was similar in all groups on all days.
Renal ACE activity and plasma renin activity. Figure 4 shows the changes in renal tissue ACE activity and Figure 5 the plasma day 7 renin levels. Treatment with both low-and high-dose trandolapril virtually abolished tissue ACE activity within 24 h. This was accompanied by an appropriate rise in plasma renin. Groups C and DI had comparable renal ACE activity throughout the study.
Renal IGF-1. On day 1 renal IGF-1 had risen to a similar extent in groups DP (514 + 62ng. g-l), DL (427 + 40 ng-gq) and DH (419 + 29 ng-g-l), all significantly higher than the basal concentration (312 + 38 ng. g-l, p < 0.01 for all). By day 2, tissue IGF-1 concentration had returned to the baseline levels in these groups and did not differ from the control animals for the remainder of the study. No rise in IGF-1 concentration above baseline was seen in groups DI, C, CL and CH.
Discussion
We have shown that in this model of experimental diabetes, despite adequate tissue ACE inhibition, renal enlargement and early accumulation of IGF-1 still occurred. This suggests that angiotensin II is not involved in early renal enlargement. Furthermore, as ACE inhibition would reduce intraglomerular pressure [13] [14] [15] this suggests that renal growth does not occur secondary to changes in renal haemodynamics and is therefore independent of renal functional changes.
It is well-established that experimental diabetes causes a marked increase in renal size within 48-72 h [16] [17] [18] , with increases in RNA, DNA and protein content implying renal growth. Renal growth is dependent upon glycaemic control and is most striking at moderate levels of hyperglycaemia (glucose 15-25 mmol. 1-1) [17] [18] [19] . Renal enlargement is associated with increased glomerular volume and tubular hypertrophy [19, 20] , and is preceded by a transient rise in renal tissue IGF-1 content, which reaches a peak 24-48 h after the induction of diabetes [6, 7] and returns to basal levels within 4 days as seen in groups DR DL and DH. These changes precede increases in kidney RNA, protein, function and size [6, 16, 21] . Kidney IGF-1 accumulation parallels thymidine incorporation in renal tubules [22] , suggesting a local mitogenic effect of IGF-1. Infusion of IGF-1 in non-diabetic rats causes renal enlargement [10] . If IGF-1 is infused in diabetic rats, 5 days after induction of diabetes when endogenous IGF-1 would have returned to normal levels, there is sustained renal growth [23] . Diabetic animals treated with insulin in order to maintain normoglycaemia show no rise in renal IGF-1 or increase in renal size. Octreotide also inhibits renal IGF-1 accumulation and renal enlargement in experimental diabetes in the short term and reduces the increase in albumin excretion seen in non-diabetic rats with increasing age [24] . These studies demonstrate that rises in endogenous or exogenous IGF-1 are required for renal enlargement suggesting that IGF-1 acts as a growth factor. How IGF-1 acts as a growth factor is unclear but stimulation of intracellular Na +/H + exchange has been suggested [25] . Angiotensin II also stimulates Na +/H + exchange [26] and could theoretically modulate the growth-promoting effects of IGF-1.
Other work in experimental diabetes has shown that both short-and long-term ( > 1year) treatment with the ACE inhibitors captopril or enalapril reduce intraglomerular pressure, GFR and single nephron GFR [13, 15] . Furthermore, treatment with ACE inhibition also prevented glomerular basement membrane thickening [27], glomerular sclerosis [13] and reduced the rise in urinary albumin excretion [13, 15, 27, 28] . It is noteworthy that despite these apparently beneficial effects wet kidney weight increased in all these studies. It is possible that different cell types within the kidney respond differently to the metabolic effects of diabetes and to ACE inhibition, so that while ACE inhibition prevents basement membrane thickening it may not prevent changes in glomerular volume or tubular growth. Zatz et al. [15] demonstrated a lesser rise in wet kidney weight in those diabetic rats treated with enalapril compared to the diabetic placebo-treated rats; however kidney weight was significantly increased compared to the control group (p < 0.05).
Thus, despite almost complete inhibition of renal ACE activity, and presumably reduction of intraglom- Values are mean+ SEM. **p < 0.01 compared to baseline IGF-1 concentrations for groups: diabetic, placebo; diabetic, low-dose trandolapril and diabetic, high-dose trandolapril erular pressure, accumulation of IGF-1 and renal enlargement still occur, his suggests that neither angiotensin II nor alterations in the renal haemodynamic abnormalities of glomerular hyperfiltration and raised intraglomerular pressure play a role in the initial renal enlargement seen in experimental diabetes. Renal accumulation of IGF-1 appears to be an important factor in early renal hypertrophy and its effects are not modulated by ACE or angiotensin II.
